Skip to main content
. 2017 Nov;58(11):1735–1742. doi: 10.2967/jnumed.117.193250

FIGURE 1.

FIGURE 1.

Anti-GPA33 DOTA-PRIT concept. (A) Schematic representation of anti-GPA33 BsAb huA33-C825 (left) and M-DOTA-Bn hapten (right), vehicle by which 177Lu treatment is administered. Anti-(M)-DOTA-Bn scFv antibody C825 has approximately equal low-pM affinity for either Y-DOTA-Bn or Lu-DOTA-Bn. (B) Schematic representation of 3-step anti-GPA33 DOTA-PRIT protocol. (Copyright 2016, reprinted with permission from Memorial Sloan Kettering Cancer Center [MSK].)